RNA in Medical Technology

Another LNA-based RNA Inhibitor Enters Clinical Trials

COPENHAGEN, March 20 /PRNewswire/ -- Santaris Pharma announced today that the fourth LNA-based drug has been brought into the clinic. In the USA several patients with cancer have now been treated with the Company's Survivin inhibitor, which is jointly developed by Santaris Pharma and Enzon Pha...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...e Isis' technology. Isis co-exclusively licensed its single-stranded rna interference (ssRNAi) technology to Alnylam as part of a new strategic init... About Isis Pharmaceuticals, Inc. Isis is exploiting its expertise in rna to discover and develop novel drugs for its product pipeline and for its pa...

Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C

...--------- Dose N Mean Change in HCV rna at Day 3 (Log(1...- PSI-7851 demonstrated potent antiviral activity with a mean HCV rna decrease of -0.49 log(10) IU/mL, -0.61 log(10) IU/mL and -1.01 log(10) IU/m...

Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)

... accumulation. The table below summarizes mean HCV rna reductions observed in this study per cohort: ... log10 or Change in HCV rna Greater Reduction in HCV Cohort Dose (log10) rna at End of Treatment ------ ---- ----...

Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV

... from baseline in viral load (log10 HIV RNA) at week 48 of treatment. A key secondary efficacy endpoint is the proportion of patients with plasma HIV rna less than 50 copies/mL at week 48 of treatment. Atazanavir boosted by ritonavir was selected for use in this study because it is recommended ...

Alfacell Provides Shareholder Update

...d as routine tool to detect the gene silencing via rna interference (RNAi) mechanism. Currently, there a...roduct candidate that works in a manner similar to rna interference (RNAi) through late-stage clinical tr...n RNase that overcomes the challenges of targeting rna for therapeutic purposes while enabling the develo...

Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions

... B. Phanavanh, C. Labbate, B.P. Monia, P.A. Kern, G. Ranganathan. ABOUT ISIS PHARMACEUTICALS, INC. Isis is exploiting its expertise in rna to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first anti...

Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection

...ficials. About Fidaxomicin Fidaxomicin is the first in a new class of antibiotics called macrocyclics, which inhibit the bacterial enzyme rna polymerase, resulting in the death of Clostridium difficile . The narrow spectrum profile of fidaxomicin may eradicate Clostridium difficile select...

Quest Diagnostics Introduces First Commercial Laboratory Test for Identifying the H1N1 Swine Flu Virus

...The Focus Diagnostics Influenza A H1N1 (Swine Flu) rna Real-Time RT-PCR Test is the first laboratory test...ics validated its new Influenza A H1N1 (Swine Flu) rna Real-Time RT-PCR Test using clinical specimens sub...technique that can detect the presence of a virus' rna from a patient's nasal or nasopharyngeal specimen....

HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials

...an indicator of disease prognosis and for use as an aid in assessing viral response to antiretroviral treatment as measured by changes in plasma HIV-1 rna levels. The assay is not intended to be used as a donor-screening test for HIV-1 or as a diagnostic test to confirm the presence of HIV-1 infection. ...

Isis and Collaborators Present New Research at the ATVB Annual Conference

...including severe neurodegenerative and metabolic diseases, and cancer." ABOUT ISIS PHARMACEUTICALS, INC. Isis is exploiting its expertise in rna to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first anti...

Clinical Update - Debio 025 in Hepatitis C

... demonstrated that Debio 025 at doses of 400 mg (with initial loading) and 800 mg daily for 29 days shows a statistically significant reduction of HCV rna of respectively -1.96 log (-98.9%) and -2.38 log (-99.5%) when co-administered with Peg-IFN alpha-2a and ribavirin in previous null responders. ...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

... reported during the 14 days of dosing, and the reductions in levels of HCV rna were significant. Results of the INFORM-1 study were presented today ... About R7128 R7128, a cytidine nucleoside analog inhibitor of HCV rna polymerase, is being developed for the treatment of chronic HCV infection. ...

InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)

...12h dosing cohorts; the most rapid declines in HCV rna occurred in the ITMN-191 900 mg q12h dosing cohort...iple combination therapy, the median change in HCV rna from baseline exceeded 5 logs in five of the six c...horts, respectively. Considering all cohorts, HCV rna was below the limit of quantification in nearly th...

ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients

...e study, ANA598 treatment resulted in rapid and sustained reductions in HCV rna with median reductions at end of treatment (Day 4) exceeding 2 log10 (>9...l load at Day 4 (12 hours after the last dose) was compared to baseline HCV rna levels. "We're very pleased with the antiviral activity and safety of ...

ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent

...ries of related chemical compounds. PG301029 is a highly novel transcriptional inhibitor of HCV replication, yielding a significant reduction of viral rna synthesis in infected cells, and laboratory studies have demonstrated the compound to be less toxic and more active than the FDA approved agent ribavi...

Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin

...nted data from a preclinical study, which utilized rna interference (RNAi) and bioinformatics to identify...llular response to brostallicin, a high-throughput rna interference screen was performed in selected ovarian cancer cell lines. rna interference is a cellular process that results in...

Cequent tkRNAi Technology to be Presented at the Centennial Meeting of the American Association for Cancer Research

...disease, announced that the company's TransKingdom rna interference ( tk RNAi) technology will be the foc...n Construct for TransKingdom rna Interference (tkRNAi) 8 am - noon Hall B-F...stance (MDR) by TransKingdom rna Interference (tkRNAi) 8 am - noon Hall B-F...

Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin

...perty protection for fidaxomicin." Fidaxomicin is the first in a new class of antibiotics called macrocyclics, which inhibit the bacterial enzyme rna polymerase, resulting in the death of Clostridium difficile . The narrow spectrum profile of fidaxomicin may eradicate Clostridium difficile select...

Landmark Study in The New England Journal of Medicine Shows HPV Testing Significantly Reduces Deaths from Cervical Cancer, Compared to other Methods Including Pap

...Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, rna and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has devel...

ExonHit Reports Proof-of-Concept in Breast Cancer Diagnostic Using its SpliceArray(TM) Platform

... breast cancer through the analysis of alternative rna splicing [1]. Study data demonstrate that exons ar... the exon level. They also provide a comprehensive rna splicing analysis across the entire human genome a...onfiguration, enabling an exhaustive monitoring of rna splice variants [2]. The Human Genome Wide SpliceA...

Quark Pharmaceuticals Presents at Asia TIDES Conference

... FREMONT, Calif., March 9 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel rna interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development presented an overvie...

Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer

...rcinoma (HCC), and a significant two-fold reduction of tumor mass. These data are being presented at the Keystone Symposium, Therapeutic Modulation of rna Using Oligonucleotides, at Lake Louise, Alberta Canada, on February 12th. Liver cancer is the third cause of cancer death globally, affecting o...

Data Suggests New Antigen-Antibody Combo Test Useful for High Volume Public Health Screening

...ve were tested individually with two different HIV rna assays. Those determined positive by both methods...ative were classified as positive after pooled HIV rna testing. The HIV antibody tests detected 90 perce... negative for HIV antibodies and positive with the rna test were then tested with the Abbott HIV Ag/Ab Co...

Clinical Update - Debio 025 in Hepatitis C

...the SOC treatment. The Company aims to evaluate whether there is an increase in the proportion of patients who achieve a sustained viral response (HCV rna < 10 U/mL 24 weeks after treatment end) with Debio 025, compared to the SOC treatment. The trial will include 272 treatment-naive chronic HCV genot...

Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function

... FREMONT, Calif., Jan. 8 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel rna interference (RNAi)-based therapeutics, today announced that it has initiated patient dosing in its Phase I/II clinical trial evaluating its systemica...

Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference

...ne Symposia Conference, Therapeutic Modulation of rna Using Oligonucleotides. The conference will be he...lly administered bacteria expressing short hairpin rna (shRNA) against beta-catenin significantly reduced messenger rna (mRNA) levels of beta-catenin in the mucosa of the...

Infant Blood May Provide Insights into Diseases Present at Birth

...d spots collected from 1998 to 2004 and the latest rna technology, researchers were able to detect over 3... filter paper," said Resau. "Even so, we got good rna test results from samples that have been in storag...archers have confirmed the stability of blood spot rna and its ability to reflect diseases, VAI researche...

Alfacell Provides ONCONASE(R) NDA Submission Update

...nce a biopharmaceutical product candidate that works in a manner similar to rna interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting rna for therapeutic purposes while enabling the development of a new class of t...

Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study

...ns approximately 2% of the outstanding common stock of OncoGenex. ABOUT ISIS PHARMACEUTICALS, INC. Isis is exploiting its expertise in rna to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first anti...

Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials

...essment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including reagents for a variety of DNA and rna analysis applications. For more information, visit http://www.hologic.com . Forward-Looking Disclaimer This News Release may contain forward-look...

Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C

...al trial. About R7227 (ITMN-191) R7227 is an inhibitor of HCV NS3/4A protease activity, and has produced multi-log10 reductions in circulating HCV rna in chronic HCV patients when administered for 14 days as monotherapy. In support of clinical studies that will combine R7227 with R7128, including the...

Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008

...EC50 value, respectively. Mean reductions of HCV rna from baseline to day seven with TMC435 alone and i...eakthrough was observed; 9/9 patients achieved HCV rna below lower limit of quantification (<25 IU/mL) and 8/9 patients achieved undetectable HCV rna (<10 IU/mL) at day 28 (RVR=89 percent). "These d...

Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers

...used in combination with multiple other agents approved or under investigation for hepatitis C. -- In a poster titled "Antiviral Efficacy of the HCV rna Polymerase Inhibitor ANA598 in the Chimpanzee Model of HCV Infection", Anadys will present data showing that ANA598 exhibits a substantial antiviral e...

InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer

...k cancer. In addition, diagnostic miRNA profiles will be developed through next-generation sequencing, in combination with InteRNA's proprietary small rna bioinformatics pipeline, miR-Intess(TM), on diverse patient sample sets provided by VUmc. "We are very excited about the opportunity of combining pr...

Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay

...tment regimen. To week 48, 65% of individuals receiving Selzentry had HIV-1 rna <50 copies/mL, compared to 69% of those individuals in the control arm of t...s, powered by the enhanced Trofile assay, 68% of individuals achieved HIV-1 rna <50 copies/mL at week 48 in both the Selzentry and efavirenz arms of the st...

Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults

... lopinavir/r for virologic response (confirmed HIV rna < 50 copies/mL). The difference between the treatm...This indication is based on analyses of plasma HIV rna levels and CD4+ cell counts from two controlled ph...eving virologic response, defined as confirmed HIV rna <50 copies/mL. Non-inferiority of PREZISTA/r vs. l...

Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project

...re-analytical platform company that has developed and commercialized reagents and kits to increase the analytical and clinical performances of DNA and rna analysis platforms including Q-PCR, microarrays, and next-gen sequencing. Its GenomePlex(TM), TransPlex(TM), and MethylPlex(TM) products achieve unbia...

Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients

...nical study of ANA598. Two additional posters will be presented on Tuesday, November 4, 2008: -- In a poster titled "Antiviral Efficacy of the HCV rna Polymerase Inhibitor ANA598 in the Chimpanzee Model of HCV Infection", Anadys will present data showing that ANA598 exhibits a substantial antiviral e...

ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis

...e cancer. ATL/TV1102 has been licensed to Teva Pharmaceutical Industries Ltd. About Isis Pharmaceuticals, Inc. Isis is exploiting its expertise in rna to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antis...